Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers

Tsao, Kuo‐Chien; Wu, Tsu‐Lan; Hong, Ji-Hong; Wu, James T.

doi:10.1002/jcla.20102

Cited by 15 publications

(13 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We learned from screening of cancer with multiple TMs that each type of cancer is not associated with the elevation of a single but TMs related to different cell types (1). For example, not only AFP was detectable in hepatoma, one could also detect elevated CEA, CA 125, PSA, and CgA in liver cancer.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis

Tsao¹,

Hong²,

Wu³

et al. 2007

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma. Both of these benign tumors are known to be at risk of developing into cancer. During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both. In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma. Many patients only had elevated CA 19-9 or CgA; the elevation of CA 125 was not detected. It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In an attempt to detect cancer at an early stage in asymptomatic population, multiple tumor markers (TMs) were used for screening (1). We noticed in our early study that elevation of multiple TMs could also be detected in individuals without malignant disease.…”

Section: Introductionmentioning

confidence: 99%

Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis

Tsao¹,

Hong²,

Wu³

et al. 2007

Clinical Laboratory Analysis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Their applications are facing great challenges, because most markers are not specific to a particular tumor. Panels of tumor markers can improve their diagnostic value (3)(4)(5). Thus a simultaneous multianalyte immunoassay with short analytical time, high throughput, small sampling volume, and low cost possesses considerable importance for cancer screening (6,7 ).…”

mentioning

confidence: 99%

A Disposable Multianalyte Electrochemical Immunosensor Array for Automated Simultaneous Determination of Tumor Markers

et al. 2007

View full text Add to dashboard Cite

Background: Automated and convenient multianalyte detection with high throughput is increasingly needed in clinical diagnosis. We developed a disposable 4-by-2 array for programmed simultaneous amperometric immunoassay of 4 tumor markers. Methods: We used a screen-printed technique, 1-step immobilization method, and flow injection technique. We immobilized carcinoembryonic antigen, ␣-fetoprotein, ␤-human choriogonadotropin, and carcinoma antigen 125 as model analytes in a redox mediator-grafted, biopolymer-modified, screen-printed carbon electrode array to capture corresponding horseradish peroxidaselabeled antibodies in competitive immunoreactions. The simultaneous multianalyte immunoassay was automatically carried out to amperometrically monitor the mediator-catalyzed enzymatic response to hydrogen peroxide, which decreased in proportion to the concentrations of analytes in samples. Results: The multianalyte immunosensor array had a throughput of 60 samples/h and allowed simultaneous detection of carcinoembryonic antigen, ␣-fetoprotein, ␤-human choriogonadotropin, and carcinoma antigen 125 in clinical serum samples with concentrations up to 188 g/L, 250 g/L, 266 IU/L, and 334 kIU/L, respectively. The detection limits (limits of the blank, mean of blank plus 3 SD) were 1.1 g/L, 1.7 g/L, 1.2 IU/L, and 1.7 kIU/L. The inter-and intraassay imprecision (CVs) of the immunosensor arrays were <7.8% and <9.0%, respectively. The immunosensor arrays were stable for 28 days.

show abstract

“…In cancer diagnostics, specificity can be improved with more than one marker (1,2). For example, cancer antigen 125 (CA 125) is elevated in different types of cancer such as endometrial cancer (3), renal cell carcinoma (4), and ovarian cancer (5).…”

Section: Introductionmentioning

confidence: 99%

Validating a Custom Multiplex ELISA Against Individual Commercial Immunoassays Using Clinical Samples

Liew

Groll²,

Thompson³

et al. 2007

BioTechniques

View full text Add to dashboard Cite

The measurement of multiple antigens in a single sample poses clinical and methodological challenges. Here we describe the validation of a multiplexed sandwich enzyme-linked immunosorbent assay (ELISA) array (microELISA) of nine antigens. The antigens tested simultaneously were: alpha-fetoprotein (AFP), prostate specific antigen (PSA), carcinoembryonic antigen (CEA), cancer antigen 125 (CA 125), CA 15-3, CA 19-9, beta-human chorionic gonadotropin (beta-hCG), luteinizing hormone (LH), and follicle stimulating hormone (FSH). At least 44 clinical samples were tested for each antigen. microELISA results for the nine antigens were then compared with clinical laboratory results obtained for the same antigens in individual chemiluminescent immunoassays. The microELISA had a coefficient of variation (cv) of 7.3% within an assay and 12.6% for assays run at different times. A statistical comparison of results from the microELISA with results from the clinical laboratory showed that the assays had correlation coefficients ranging from 0.99 to 0.76, and Deming regression demonstrated that four of the nine assays were high-quality assays and not statistically different to the individual assays. To determine if the differences in the assays were due to methodology, the microELISA was also compared with conventional ELISAs using identical antibodies and reagents. Deming regression demonstrated that five of the eight assays were high-quality, indicating that a poor correlation between a microELISA and an individual immunoassay are partly due to antibody differences.

show abstract

Detection of carcinomas in an asymptomatic Chinese population: advantage of screening with multiple tumor markers

Cited by 15 publications

References 9 publications

Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis

Elevation of CA 19‐9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis

A Disposable Multianalyte Electrochemical Immunosensor Array for Automated Simultaneous Determination of Tumor Markers

Validating a Custom Multiplex ELISA Against Individual Commercial Immunoassays Using Clinical Samples

Contact Info

Product

Resources

About